Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Name: Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
License: Public Domain

Icahn School of Medicine at Mount Sinai

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

prostatecancer

prostate cancer, high-risk prostate cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 174877
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.